Patch nicotine is a transdermal patch that releases nicotine in the body through the skin. This is used as an aid in nicotine replacement therapy (NRT), a process for quitting smoking.
Video Nicotine patch
Medical use
Dozens of clinical trials have shown that patches are about double the success rate over placebo treatment. The placebo test showed a success rate of 5.9%, compared with a blindness test of 7.2%, and an open test of 10.8%.
Maps Nicotine patch
History
The first pharmacokinetic study of the transdermal nicotine patch on humans was published in 1984 by Jed E. Rose, Ph.D., Murray E. Jarvik, M.D., Ph.D. and K. Daniel Rose, and followed by publications by Rose et al. (1985) from studies of smokers suggesting that transdermal nicotine patches reduce the desire for cigarettes. Frank Etscorn Ph.D. filed a patent in the United States on January 23, 1985 and issued a patent on July 1, 1986. The University of California applied for a patent that competed almost 3 years after the Etscorn filing on February 19, 1988, granted May 1, 1990. Furthermore, The US Patent Office declared interference and, after a thorough review of the conception, reduction to the practice and date of filing a patent, was issued on 29 September 1993 a priority decision in favor of Rose et al. patent.
Research
The nicotine patch is in research to help relieve the symptoms of post-operative pain and to treat early dementia.
Studies are underway on the use of transdermal nicotine patches to treat anxiety, depression, and no attention to subjects with ADHD and to treat late-life depression.
Transdermal nicotine patches can be used to relieve symptoms of ulcerative colitis. However, this does not occur in Crohn's disease, the same health conditions, where smoking and nicotine intake generally aggravate the effects of the disease.
See also
- Smoking cess
- Nicotine replacement therapy
- Nicotine candy
- Gum
- Transdermal patch
References
Source of the article : Wikipedia
0 Comments